- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Aclaris Therapeutics' IPO Priced Well Below Expected Range
Aclaris Therapeutics’ (NASDAQ:ACRS) IPO priced well below its expected its expected range, in the face of a bearish biotech market. The company raised $55 million.
Aclaris Therapeutics’ (NASDAQ:ACRS) IPO priced well below its expected its expected range, in the face of a bearish biotech market. The company raised $55 million.
According to Fierce Biotech:
The company moved 5 million shares at $11 apiece, coming in short of its $14-to-$16 projections. Aclaris is also offering another 750,000 shares to underwriters over 30 days, setting the maximum deal value at more than $60 million.
Aclaris’ IPO follows a $40 million Series C fundraise last month, cash the company is putting toward a pipeline of topical treatments for skin disorders. Leading the way is A-101, which treats a nonmalignant skin tumor called seborrheic keratosis, or SK. After a trio of Phase II successes, A-101 is slated to enter three Phase III trials in the first quarter of next year, Aclaris said, on track for an FDA submission by the end of 2016. The company is also mapping out a Phase II program for A-101 as a treatment for warts.
In September, Aclaris broadened its pipeline by trading $8 million up front for the rights to some early-stage JAK inhibitors from Rigel Pharmaceuticals ($RIGL), which the company plans to develop as treatments for alopecia.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â